International Center For Diarrhoeal Diseases & Research Icddrb

Dhaka, Bangladesh

International Center For Diarrhoeal Diseases & Research Icddrb

Dhaka, Bangladesh
SEARCH FILTERS
Time filter
Source Type

Maruf S.,International Center For Diarrhoeal Diseases & Research Icddrb | Nath P.,Mymensingh Medical College and Hospital | Aktar F.,International Center For Diarrhoeal Diseases & Research Icddrb | Basher A.,Mymensingh Medical College and Hospital | Basher A.,Surya Kanta Kala azar Research Center
Pharmacology Research and Perspectives | Year: 2016

Although liposomal amphotericin B (AmBisome) is considered as the first-line treatment for New Kala-azar, there is not enough evidence on the dosage formulation in children and its effect on them. Being considered as the safest drug for treatment of Kala-azar, this case of AmBisome-induced avascular necrosis now gives rise to the question; whether it is actually safe enough and if a dosage modification is needed in case of children. This so far, to the best of our knowledge, is the first instance of such severe adverse event due to AmBisome administration. © 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.

Loading International Center For Diarrhoeal Diseases & Research Icddrb collaborators
Loading International Center For Diarrhoeal Diseases & Research Icddrb collaborators